ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 245 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $19,887,002 | +145.2% | 830,355 | +92.7% | 0.24% | +114.5% |
| Q1 2023 | $8,109,632 | +25.3% | 430,905 | +8.9% | 0.11% | +22.2% |
| Q3 2022 | $6,471,000 | +76.7% | 395,549 | +52.2% | 0.09% | +60.7% |
| Q2 2022 | $3,663,000 | -62.3% | 259,967 | -37.5% | 0.06% | -59.7% |
| Q4 2021 | $9,714,000 | -0.7% | 416,200 | -29.3% | 0.14% | -13.1% |
| Q3 2021 | $9,781,000 | -39.5% | 588,859 | -11.2% | 0.16% | -47.0% |
| Q2 2021 | $16,172,000 | +60.5% | 663,054 | +69.8% | 0.30% | +34.8% |
| Q1 2021 | $10,077,000 | +270.2% | 390,591 | +667.2% | 0.22% | +211.1% |
| Q4 2020 | $2,722,000 | -79.8% | 50,913 | -84.5% | 0.07% | -83.7% |
| Q3 2020 | $13,506,000 | +352.5% | 327,415 | +431.7% | 0.44% | +275.4% |
| Q2 2020 | $2,985,000 | – | 61,575 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |